Think it was just the lull we had to get through as they pivoted from full-bore ART to building the full pipeline of generics at all stages of the approval process. Now finally seeing the blooming of the planted seeds.
Still don’t think the stock was ever truly “worth” as low as mid 2s, should’ve been higher all along.
There was an increase in sales. I looked for profits but did not find anything mention of profits. I'll definitely keep an eye on ELTP over the coming weeks and months.